 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for July 19, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| EBAY... | Hot Stocks19:52 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Walt Disney (DIS) has dramatically slashed its advertising spending on Facebook (FB), the latest setback for the tech giant as it faces a boycott from companies upset with its handling of hate speech and divisive content, The Wall Street Journal's Suzanne Vranica reported, citing people familiar with the matter. Disney was Facebook's top U.S. advertiser for the first six months of 2020, research company Pathmatics estimates. It joins hundreds of other companies that have paused spending, including Unilever (UL), Starbucks (SBUX), Ford (F), Verizon (VZ), and many small marketers. 2. eBay (EBAY) would prefer to keep a stake in the classified advertising business it's selling, lessening the chances Prosus NV will win the hotly-contested auction, according to Bloomberg, citing people familiar with the matter. The decision at a board meeting gives a surprise boost to a bid from Norwegian online marketplace Adevinta ASA, which offered a mix of cash and stock and would leave eBay with a significant stake in the combine busines, the people said. A combination of the classifieds unit with the listed Scandinavian company would also allow eBay to benefit from any future increase in the shares, they added. A private equity consortium backed by Blackstone (BX), Permira and Hellman & Friedman has separately been pursuing the unit and also offered to let eBay keep a minority stake, according to the publication. 3. Chipotle's (CMG) use of a downloadable app, along with some menu innovations, has likely saved it from the harsh fate of many other restaurants, Steven Sears wrote in this week's edition of Barron's. At a time when most people are avoiding restaurants because of fears of COVI-19, and when many others are shuttered, Chipotle has kept business rather brisk, the author noted. 4. Quest Diagnostics (DGX) announced that it has received emergency use authorization from the U.S. Food and Drug Administration to use specimen pooling with its proprietary molecular diagnostic test for COVID-19. Quest is the first lab provider to receive FDA authorization for the technique for COVID-19 testing in the United States. In pooling, specimens must still be collected into individual vials, but then are combined into small batches or pools by the laboratory. A negative result for a batch means that all patients in that pool are considered negative - If a positive result occurs for the batch, each specimen is retested individually. The technique is an efficient way to evaluate patients in regions or populations with low rates of disease. Pooling is used routinely in blood banking to screen donated blood for a variety of viruses, among other applications. With the new pooling EUA, the Quest Diagnostics SARS-CoV-2 RNA test may be used with pooled upper respiratory specimens - nasopharyngeal, mid-turbinate, anterior nares or oropharyngeal swabs. 5. MSCI (MSCI), S&P Global (SPGI), Dollar General (DG), Graham Holdings (GHC), Wells Fargo (WFC) and Goldman Sachs (GS) saw positive mentions in this week's edition of Barron's.
|
| RHHBY DGX | Hot Stocks14:01 EDT FDA authorizes Quest COVID-19 diagnostic testing for specimen pooling for EUA - Quest Diagnostics (DGX) announced that it has received emergency use authorization from the U.S. Food and Drug Administration to use specimen pooling with its proprietary molecular diagnostic test for COVID-19. Quest is the first lab provider to receive FDA authorization for the technique for COVID-19 testing in the United States. In pooling, specimens must still be collected into individual vials, but then are combined into small batches or pools by the laboratory. A negative result for a batch means that all patients in that pool are considered negative - If a positive result occurs for the batch, each specimen is retested individually. The technique is an efficient way to evaluate patients in regions or populations with low rates of disease. Pooling is used routinely in blood banking to screen donated blood for a variety of viruses, among other applications. With the new pooling EUA, the Quest Diagnostics SARS-CoV-2 RNA test may be used with pooled upper respiratory specimens - nasopharyngeal, mid-turbinate, anterior nares or oropharyngeal swabs. In clinical data presented by Quest to the FDA, none of 3,091 total specimens from a population with a prevalence rate of 1%-10%, if pooled, would have been incorrectly determined to be negative. The company expects to deploy the technique at its laboratories in Chantilly, VA and Marlborough, Mass., by the end of next week with additional laboratories to follow. On July 13, 2020, Quest issued a statement that soaring demand for COVID-19 molecular diagnostics is slowing turnaround times to report results. On Friday, the FDA also granted three emergency use authorizations to Quest Diagnostics for the use of its Quest Diagnostics Self-Collection Kit with the Hologic Panther Fusion, Hologic Aptima and Roche (RHHBY) cobas molecular platforms. The new EUAs expand the use of the self-collection kit beyond the EUA, granted on May 27th, for the use of the kit on the Quest SARS-CoV-2 rRT-PCR test. The company expects the new EUAs will allow it to use self-collection more broadly on behalf of clients and patients in the United States. Self-collected specimens that were not observed by a healthcare professional are not eligible for pooling. In March 2020, Quest received FDA EUA for The Quest Diagnostics SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. In May 2020, the company received an FDA EUA to use the test nasal swab specimens that are self-collected at home or in a healthcare setting by individuals using an authorized home-collection kit when determined to be appropriate by a healthcare provider.
|
| QDEL | Hot Stocks08:39 EDT Quidel Sofia SARS antigen FIA updates EUA performance data to 96.7% PPA vs. PCR - Quidel announced today that it has updated the performance data for its Sofia SARS Antigen FIA test on its package insert to 96.7% using direct nasal swab specimens versus PCR as a result of further studies included in its amended Emergency Use Authorization that were submitted to the U.S. Food and Drug Administration. The U.S. Department of Health and Human Services has indicated its intent to purchase both Sofia 2 instruments and the Sofia SARS Antigen FIA for distribution and use in nursing homes. Under the proposed terms, HHS will purchase 2,000 Sofia instruments and 750,000 Sofia SARS Antigen FIA tests over the next few months to expand access to COVID-19 testing in nursing homes throughout the U.S. Separately, the Sofia SARS Antigen FIA received CE Mark for use with the Sofia and Sofia 2 instruments. The CE Mark allows Quidel to market and sell the Sofia SARS Antigen FIA in Europe, as well as other countries that accept the CE Mark.
|
